Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.

Animals Mice Immunity, Humoral SARS-CoV-2 / genetics COVID-19 Antibodies Adjuvants, Immunologic Mice, Inbred BALB C Antibodies, Neutralizing Antibodies, Viral Spike Glycoprotein, Coronavirus / genetics

Journal

Archives of virology
ISSN: 1432-8798
Titre abrégé: Arch Virol
Pays: Austria
ID NLM: 7506870

Informations de publication

Date de publication:
23 Jun 2023
Historique:
received: 26 10 2022
accepted: 05 03 2023
medline: 26 6 2023
pubmed: 23 6 2023
entrez: 23 6 2023
Statut: epublish

Résumé

Due to the rapid development of new variants of SARS-CoV-2 as well as the real threat of new coronavirus zoonosis events, the development of a preventive vaccine with a broader scope of functionality is highly desirable. Previously, we reported the functionality of a nasal formulation containing the nucleocapsid protein and the receptor-binding domain (RBD) of the spike protein of the Delta variant of SARS-CoV-2 combined with the ODN-39M adjuvant. This combination induced cross-reactive immunity in mucosal and systemic compartments at the sarbecovirus level. In the present study, we explored the magnitude of the immunity generated in BALB/c mice by the same formulation with alum added as an additional adjuvant, to enhance the humoral immunity against the two antigens. Animals were immunized with three doses of the bivalent formulation, administered by subcutaneous route. Humoral immunity was tested by ELISA, and the neutralizing capacity of the resulting antibodies (Abs) was evaluated using a surrogate test and a vesicular stomatitis virus (VSV) pseudovirus-based assay. Cell-mediated immunity was also investigated using an IFN-γ ELISpot assay. High levels of antibodies against both antigens (N and RBD) were obtained upon immunization. Anti-RBD Abs with neutralizing capacity reacted with the RBD of three SARS-CoV-2 variants tested, including Omicron. Abs recognizing the nucleocapsid proteins of SARS-CoV-1 and the SARS-CoV-2 Delta and Omicron variants were also detected. Taken together, these results suggest that this bivalent formulation could be an attractive component of a pancorona vaccine able to broaden the scope of humoral immunity against both antigens. This will be particularly important for the reinforcement of immunity in previously vaccinated and/or infected populations.

Identifiants

DOI: 10.1007/s00705-023-05812-8 PMID: 37351679
pubmed: 37351679
doi: 10.1007/s00705-023-05812-8
pii: 10.1007/s00705-023-05812-8
doi:

Substances chimiques

Antibodies 0
Adjuvants, Immunologic 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

190

Subventions

Organisme : National key R&D program of China
ID : 2021YFE0192200
Organisme : Hunan Provincial Base for Scientific and Technological Innovation Cooperation
ID : 2019CB1012
Organisme : The Science and Technology Innovation Program of Hunan Province
ID : 2020RC5035
Organisme : Hunan Provincial Innovative Construction Program
ID : 2020WK2031

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Références

Thakur V, Bhola S, Thakur P, Patel SKS, Kulshrestha S, Ratho RK, Kumar P (2022) Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection 50:309–325. https://doi.org/10.1007/s15010-021-01734-2
doi: 10.1007/s15010-021-01734-2 pubmed: 34914036
Swerdlow DL, Finelli L (2020) Preparation for possible sustained transmission of 2019 novel coronavirus: lessons from previous epidemics. JAMA 323:1129–1130. https://doi.org/10.1001/jama.2020.1960
doi: 10.1001/jama.2020.1960 pubmed: 32207807
Rubin R (2021) The search for a single vaccine against coronaviruses yet to come. JAMA 326(2):118–120. https://doi.org/10.1001/jama.2021.9477
doi: 10.1001/jama.2021.9477 pubmed: 34160567
Morens DM, Taubenberger JK, Fauci AS (2022) Universal coronavirus vaccines—an urgent need. N Engl J Med 386:297–299. https://doi.org/10.1056/NEJMp2118468
doi: 10.1056/NEJMp2118468 pubmed: 34910863
Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell AM, Simons D, Blomquist PB, Zaidi A, Nash S, Iwani Binti Abdul Aziz N, Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R, Ladhani SN, Ferguson N, Zambon M, Campbell CNJ, Brown K, Hopkins S, Chand M, Ramsay M, Lopez Bernal J (2022) Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 386:1532–1546. https://doi.org/10.1056/NEJMoa2119451
doi: 10.1056/NEJMoa2119451 pubmed: 35249272
Dutta NK, Mazumdar K, Gordy JT (2020) The nucleocapsid protein of SARS–CoV-2: a target for vaccine development. J Virol 94:e00647-e720. https://doi.org/10.1128/JVI.00647-20
doi: 10.1128/JVI.00647-20 pubmed: 32546606 pmcid: 7307180
Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, Wijeyesinghe S, Soerens AG, Becker S, Thiede JM, Weyu E, O’Flanagan SD, Walter JA, Vu MN, Menachery VD, Bold TD, Vezys V, Jenkins MK, Langlois RA, Masopust D (2021) Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. JI 207:376–379. https://doi.org/10.4049/jimmunol.2100421
doi: 10.4049/jimmunol.2100421
Dangi T, Class J, Palacio N, Richner JM, Penaloza MacMaster P (2021) Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep 36:109664. https://doi.org/10.1016/j.celrep.2021.109664
doi: 10.1016/j.celrep.2021.109664 pubmed: 34450033 pmcid: 8367759
Phatarphekar A, Vidyadhar Reddy GEC, Gokhale A, Karanam G, Kuchroo P, Shinde K, Masand G, Pagare S, Khadpe N, Pai SS, Vijayan V, Ramnath RL, Pratap Reddy K, Rao P, Harinarayana Rao S, Ramana V (2022) RelCoVax
doi: 10.1016/j.vaccine.2022.06.026 pubmed: 35718590 pmcid: 9189014
Lobaina Y, Chen R, Suzarte E, Ai P, Huerta V, Musacchio A, Silva R, Tan C, Martin A, Lazo L, Guillén G, Yang K, Perera Y, Hermida L (2022) The nucleocapsid protein of SARS-CoV-2, combined with ODN-39M, is a potential component for an intranasal bivalent pancorona vaccine (preprint). Immunology. https://doi.org/10.1101/2022.06.02.494502
doi: 10.1101/2022.06.02.494502
Gil L, Marcos E, Izquierdo A, Lazo L, Valdés I, Ambala P, Ochola L, Hitler R, Suzarte E, Álvarez M, Kimiti P, Ndung’u J, Kariuki T, Guzmán MG, Guillén G, Hermida L (2015) The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immunol Cell Biol 93:57–66. https://doi.org/10.1038/icb.2014.63
doi: 10.1038/icb.2014.63 pubmed: 25178969
Lobaina Y, Trujillo H, García D, Gambe A, Chacon Y, Blanco A, Aguilar JC (2010) The effect of the parenteral route of administration on the immune response to simultaneous nasal and parenteral immunizations using a new HBV therapeutic vaccine candidate. Viral Immunol 23:521–529. https://doi.org/10.1089/vim.2010.0024
doi: 10.1089/vim.2010.0024 pubmed: 20883166
Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y (2020) Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 15:3699–3715. https://doi.org/10.1038/s41596-020-0394-5
doi: 10.1038/s41596-020-0394-5 pubmed: 32978602
Scheiermann J, Klinman DM, Klinman D (2014) Vaccines targeting infectious diseases and cancer. Exp Rev Vaccines 32(48):6377–6389. https://doi.org/10.1016/j.vaccine.2014.06.065
doi: 10.1016/j.vaccine.2014.06.065
Olivera S, Pérez A, Falcon V, Urquiza D, Pichardo D, Martínez-Donato G (2020) Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice. Adv Virol 165:593–607. https://doi.org/10.1007/s00705-019-04464-x
doi: 10.1007/s00705-019-04464-x
Aguilar JC, Lobaina Y, Muzio V, Garcia D, Penton E, Iglesias E, Pichardo D, Urquiza D, Rodriguez D, Silva D, Petrovsky N, Guillen G (2004) Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 82:539–546. https://doi.org/10.1111/j.1440-1711.2004.01278.x
doi: 10.1111/j.1440-1711.2004.01278.x pubmed: 15479440
Hong S-H, Oh H, Park YW, Kwak HW, Oh EY, Hyo-Jung P, Kang KW, Kim G, Koo B-S, Hwang E-H, Baek SH, Hyeong-Jun P, Lee Y-S, Bang Y-J, Kim J-Y, Bae S-H, Lee SJ, Seo K-W, Hak K, Kwon T, Kim J-H, Lee S, Kim E, Kim Y, Park J-H, Park S-I, Gonçalves M, Weon BM, Jeong H, Nam KT, Hwang K-A, Kim J, Hun K, Lee S-M, Hong JJ, Nam J-H (2021) Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates. Sci Adv 7:7156. https://doi.org/10.1126/sciadv.abg7156
doi: 10.1126/sciadv.abg7156
Matchett WE, Joag JV, Stolley M, Shepherd FK, Quarnstrom CK, Mickelson SW, Soerens AG, Becker S, Thiede JM, Weyu E, O’Flanagan SD, Walter JA, Vu MN, Vineet D, Menachery TD, Bold VV, Jenkins MK, Langlois RA, Masopust D (2021) Cutting Edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J Immunol 207:376–379. https://doi.org/10.4049/jimmunol.2100421
doi: 10.4049/jimmunol.2100421 pubmed: 34193597
Harris PE, Brasel T, Massey C, Herst CV, Burkholz S, Lloyd P, Blankenberg T, Bey TM, Carback R, Hodge T, Ciotlos S, Wang L, Comer JE, Rubsamen RM (2021) A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques. Vaccines 9(5):520. https://doi.org/10.3390/vaccines9050520
doi: 10.3390/vaccines9050520 pubmed: 34070152 pmcid: 8158516
Zhuang Z, Lai X, Sun JJ, Chen Z, Zhang Z, Dai J, Liu D, Li Y, Li F, Wang Y, Zhu A, Wang J, Yang W, Huang J, Li X, Hu L, Wen L, Zhuo J, Zhang Y, Chen D, Li S, Huang S, Yongxia S, Zheng K, Nanshan Z, Jingxian Z, Zhou D, Zhao JJ (2021) Mapping and role of T cell response in SARS-CoV-2–infected mice. J Exp Med 218(4):e20202187. https://doi.org/10.1084/jem.20202187
doi: 10.1084/jem.20202187 pubmed: 33464307 pmcid: 7814348
Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, Zhu H, Liu J, Xu Y, Xie J, Morioka H, Sakaguchi N, Qin C, Liu G (2016) Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2(5):361–376. https://doi.org/10.1021/acsinfecdis.6b00006
doi: 10.1021/acsinfecdis.6b00006 pubmed: 27627203 pmcid: 7075522
Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan T, Peng B-H, Couch RB, Tseng C-TK (2016) Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12(9):2351–2356. https://doi.org/10.1080/21645515.2016.1177688
doi: 10.1080/21645515.2016.1177688 pubmed: 27269431 pmcid: 5027702
Li X, Huang Y, Wang W, Jing GL, Zhang CH, Qin PZ, Guan WJ, Gan L, Li YL, Liu WH, Dong H, Miao YT, Fan SJ, Zhang ZB, Zhang DM, Zhong NS (2021) Effectiveness of inactivated SARSCoV- 2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real world study. Emerg Microbes Infect 10(1):1751–1759. https://doi.org/10.1080/22221751.2021.1969291
doi: 10.1080/22221751.2021.1969291 pubmed: 34396940 pmcid: 8425710
Li D, Luan N, Li J, Zhao H, Zhang Y, Long R, Jiang G, Fan S, Xu X, Cao H, Wang Y, Liao Y, Wang L, Liu L, Liu C, Li Q (2021) Waning antibodies from inactivated SARS-CoV-2 vaccination offer protection against infection without antibody-enhanced immunopathology in rhesus macaque pneumonia models. Emerg Microbes Infect 10(1):2194–2198. https://doi.org/10.1080/22221751.2021.2002670
doi: 10.1080/22221751.2021.2002670 pubmed: 34736354 pmcid: 8635581
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL (2022) Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1–2 clinical trial (ABDALA Study). eClinicalMedicine 46:101383. https://doi.org/10.1016/j.eclinm.2022.101383
doi: 10.1016/j.eclinm.2022.101383 pubmed: 35434578 pmcid: 8994669
Pérez-Rodríguez S, Rodríguez-González MC, Ochoa-Azze R, Climent-Ruiz Y, González-Delgado CA, Paredes-Moreno V-S, Rodríguez-Noda L, Perez-Nicado R, González-Mugica R, Martínez-Pérez M, Sánchez-Ramírez B, Hernández-García T, Díaz-Machado A, Tamayo-Rodríguez M, Martín-Trujillo A, Rubino-Moreno J, Suárez-Batista A, Dubed-Echevarría M, Pérez-Guevara MT, Amoroto-Roig M, Chappi-Estévez Y, Bergado-Báez G, Pi-Estopiñán F, Chen GW, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V (2022) A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: safety, reactogenicity and immunogenicity. Vaccine 40:2068–2075. https://doi.org/10.1016/j.vaccine.2022.02.029
doi: 10.1016/j.vaccine.2022.02.029 pubmed: 35164986 pmcid: 8823954
Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, Wu C, Zhong Z, Wang F, Duan X, Tian S, Wu L, Liu Y, Luo Y, Chen Z, Li F, Li J, Yu X, Ren H, Liu L, Meng S, Yan J, Hu Z, Lidong Gao L, Gao GF (2021) Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 21(8):P1107–P1119. https://doi.org/10.1016/S1473-3099(21)00127-4
doi: 10.1016/S1473-3099(21)00127-4
Dangi T, Sanchez S, Park M, Class J, Richner JM, Penaloza-MacMaster P (2022) Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2 (preprint). Immunology. https://doi.org/10.1101/2022.03.09.483635
doi: 10.1101/2022.03.09.483635
Herman JD, Wuang C, Burke JS, Zur Y, Compere H, Kang J, Macvicar R, Shin S, Frank I, Siegel D, Tebas P, Choi GH, Shaw PA, Yoon H, Liise-annePirofski L-A, Juelg B, Bar KJ, Lauffenburger D, Alter G (2022) A role for nucleocapsid-specific antibody function in Covid-19. Convalescent Plasma Ther (Preprint). https://doi.org/10.1101/2022.02.19.22271230
doi: 10.1101/2022.02.19.22271230
Caddy SL, Vaysburd M, Papa G, Wing M, O’Connell K, Stoycheva D, Foss S, Terje Andersen J, Oxenius A, James LC (2021) Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J. https://doi.org/10.15252/embj.202010622
doi: 10.15252/embj.202010622 pubmed: 34323299 pmcid: 8408615
Tilocca B, Soggiu A, Sanguinetti M, Musella V, Britti D, Bonizzi L, Urbani A, Roncada P (2020) Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes Infect 22:188–194. https://doi.org/10.1016/j.micinf.2020.04.002
doi: 10.1016/j.micinf.2020.04.002 pubmed: 32302675 pmcid: 7156246
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP (2021) Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27:1205–1211. https://doi.org/10.1038/s41591-021-01377-8
doi: 10.1038/s41591-021-01377-8 pubmed: 34002089
Zhu DY, Gorman MJ, Yuan D, Yu J, Mercado NB, McMahan K, Borducchi EN, Lifton M, Liu J, Nampanya F, Patel S, Peter L, Tostanoski LH, Pessaint L, Ry AV, Finneyfrock B, Velasco J, Teow E, Brown R, Cook A, Andersen H, Lewis MG, Lauffenburger DA, Barouch DH, Alter G (2022) Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. PLOS Biol 20:e3001609. https://doi.org/10.1371/journal.pbio.3001609
doi: 10.1371/journal.pbio.3001609 pubmed: 35512013 pmcid: 9071142
Kleanthous H, Silverman JM, Makar KW, Yoon I-K, Jackson N, Vaughn DW (2021) Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. npj Vaccines 6:128. https://doi.org/10.1038/s41541-021-00393-6
doi: 10.1038/s41541-021-00393-6 pubmed: 34711846 pmcid: 8553742
Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas Ramos G, Dopfer-Jablonka A, Heidemann A, Ritter C, Friedrichsen M, Schultze-Florey C, Ravens I, Willenzon S, Bubke A, Ristenpart J, Janssen A, Ssebyatika G, Bernhardt G, Münch J, Hoffmann M, Pöhlmann S, Krey T, Bošnjak B, Förster R, Behrens MN (2021) Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1nCoV-19/BNT162b2 vaccination. Nat Med 27:1525–1529. https://doi.org/10.1038/s41591-021-01449-9
doi: 10.1038/s41591-021-01449-9 pubmed: 34262158 pmcid: 8440184
Lee B, Ko J-H, Park J, Moon H-W, Baek JY, Jung S, Lim H-Y, Kim K-C, Huh K, Cho SY, Kang C-I, Chung DR, Huh HJ, Chung CR, Kim Y-J, Joo E-J, Kang E-S, Peck KR (2022) Estimating the neutralizing effect and titer correlation of semi-quantitative anti-SARS-CoV-2 antibody immunoassays. Front Cell Infect Microbiol 12:822599. https://doi.org/10.3389/fcimb.2022.822599
doi: 10.3389/fcimb.2022.822599 pubmed: 35493733 pmcid: 9046723
Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, Hu Z, Chih-Wei Chen V, Young BE, Sia WR, Tan Y-J, Foo R, Yi Y, Lye DC, Anderson DE, Wang L-F (2020) A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol 38:1073–1078. https://doi.org/10.1038/s41587-020-0631-z
doi: 10.1038/s41587-020-0631-z pubmed: 32704169
Yuan M, Wu NC, Zhu X, Lee CC, So R, Lv H, Mok C, Wilson IA (2020) A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 368(6491):630–633. https://doi.org/10.1126/science.abb7269
doi: 10.1126/science.abb7269 pubmed: 32245784 pmcid: 7164391
Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R (2004) Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 85:2407–2419. https://doi.org/10.1099/vir.0.79869-0
doi: 10.1099/vir.0.79869-0 pubmed: 15269383

Auteurs

Yadira Lobaina (Y)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Research Department, Yongzhou Zhong Gu Biotechnology Co., Ltd, Yangjiaqiao Street, Lengshuitan District, Yongzhou, 425000, Hunan, China.

Rong Chen (R)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Yongzhou Development and Construction Investment Co. Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou, Hunan, China.

Edith Suzarte (E)

Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600, Havana, Cuba.

Panchao Ai (P)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Yongzhou Development and Construction Investment Co. Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou, Hunan, China.

Vivian Huerta (V)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600, Havana, Cuba.

Changyuan Tan (C)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Yongzhou Development and Construction Investment Co. Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou, Hunan, China.

Liz Alvarez-Lajonchere (L)

Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600, Havana, Cuba.

Yang Liling (Y)

Department of Laboratory Medicine, Dongguan Ninth People's Hospital, No. 88, Shaditang, Guancheng District, Dongguan, Guangdong, China.

Alexis Musacchio (A)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600, Havana, Cuba.

Ricardo Silva (R)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China.
Scientific Department, Representative Office of BioCubaFarma in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing, 100022, China.

Gerardo Guillén (G)

Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600, Havana, Cuba.

Jiang Zaixue (J)

Guangdong Eighth People's Hospital, No. 68 South, Shilong Xihu 3rd Road, Shilong Town, Dongguan, Guangdong, China.

Ke Yang (K)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China. young@ccbjic.com.
Yongzhou Development and Construction Investment Co. Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou, Hunan, China. young@ccbjic.com.

Yasser Perera (Y)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China. ypereranegrin@ccbjic.com.
Biomedical Research Department, Center for Genetic Engineering and Biotechnology (CIGB), 10600, Havana, Cuba. ypereranegrin@ccbjic.com.
Research Department, Yongzhou Zhong Gu Biotechnology Co., Ltd, Yangjiaqiao Street, Lengshuitan District, Yongzhou, 425000, Hunan, China. ypereranegrin@ccbjic.com.

Lisset Hermida (L)

Research Department, China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Lengshuitan District, Yongzhou, 425000, Hunan, China. lissethermida@biocubafarmacu.com.
Scientific Department, Representative Office of BioCubaFarma in China, Jingtai Tower, No. 24 Jianguomen Wai Street, Chaoyang District, Beijing, 100022, China. lissethermida@biocubafarmacu.com.
Yongzhou Development and Construction Investment Co. Ltd. (YDCI), Changfeng Industry Park, Yongzhou Economic and Technological Development Zone, No. 1 Liebao Road, Lengshuitan District, Yongzhou, Hunan, China. lissethermida@biocubafarmacu.com.
ORCID: 0000-0001-8470-183X

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité humorale › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Adjuvants immunologiques › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Broad humoral immunity generated in mice by a...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Broad humoral immunity generated in mice by a...